These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37305581)

  • 1. Indolyl-chalcone derivatives trigger apoptosis in cisplatin-resistant mesothelioma cells through aberrant tubulin polymerization and deregulation of microtubule-associated proteins.
    Steinlein S; Essmann F; Ghilardi AF; Horn H; Schüler J; Hausser A; Sun L; Ott G; Kalla C
    Front Oncol; 2023; 13():1190988. PubMed ID: 37305581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel indolyl-chalcones target stathmin to induce cancer cell death.
    Wegiel B; Wang Y; Li M; Jernigan F; Sun L
    Cell Cycle; 2016 May; 15(9):1288-94. PubMed ID: 26986925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways.
    Sun R; Tanino R; Tong X; Haque EF; Amano Y; Isobe T; Tsubata Y
    Transl Lung Cancer Res; 2022 Apr; 11(4):543-559. PubMed ID: 35529797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
    Suraokar MB; Nunez MI; Diao L; Chow CW; Kim D; Behrens C; Lin H; Lee S; Raso G; Moran C; Rice D; Mehran R; Lee JJ; Pass HI; Wang J; Momin AA; James BP; Corvalan A; Coombes K; Tsao A; Wistuba II
    Ann Oncol; 2014 Jun; 25(6):1184-92. PubMed ID: 24669013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma.
    Birnie KA; Yip YY; Ng DC; Kirschner MB; Reid G; Prêle CM; Musk AW; Lee YC; Thompson PJ; Mutsaers SE; Badrian B
    Mol Cancer Res; 2015 Jul; 13(7):1106-18. PubMed ID: 25824152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
    Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T
    Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
    Zanellato I; Colangelo D; Osella D
    Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability.
    Du S; Sarver JG; Trabbic CJ; Erhardt PW; Schroering A; Maltese WA
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):237-254. PubMed ID: 30426158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
    Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
    Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in
    Oehl K; Vrugt B; Wagner U; Kirschner MB; Meerang M; Weder W; Felley-Bosco E; Wollscheid B; Bankov K; Demes MC; Opitz I; Wild PJ
    Clin Cancer Res; 2021 Apr; 27(8):2277-2291. PubMed ID: 33547197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
    Kopecka J; Salaroglio IC; Righi L; Libener R; Orecchia S; Grosso F; Milosevic V; Ananthanarayanan P; Ricci L; Capelletto E; Pradotto M; Napoli F; Di Maio M; Novello S; Rubinstein M; Scagliotti GV; Riganti C
    Lung Cancer; 2018 Jun; 120():34-45. PubMed ID: 29748013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
    Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
    Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma.
    Denis I; Cellerin L; Gregoire M; Blanquart C
    Oncotarget; 2014 Nov; 5(22):11641-52. PubMed ID: 25361002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Mukhopadhyay L; Dong L; Yeap BY; Sugarbaker DJ; Bueno R
    J Pathol; 2007 Mar; 211(4):439-46. PubMed ID: 17253597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-Associated Fibroblasts Regulate Kinase Activity in Mesothelioma Cell Lines via Paracrine Signaling and Thereby Dictate Cell Faith and Behavior.
    Mathilakathu A; Wessolly M; Mairinger E; Uebner H; Kreidt D; Brcic L; Steinborn J; Greimelmaier K; Wohlschlaeger J; Schmid KW; Mairinger FD; Borchert S
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Numb suppresses tumor cell growth and enhances sensitivity to cisplatin in epithelioid malignant pleural mesothelioma.
    Kang Y; Ding M; Tian G; Guo H; Wan Y; Yao Z; Li B; Lin D
    Oncol Rep; 2013 Jul; 30(1):313-9. PubMed ID: 23624653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma.
    Borchert S; Suckrau PM; Walter RFH; Wessolly M; Mairinger E; Steinborn J; Hegedus B; Hager T; Herold T; Eberhardt WEE; Wohlschlaeger J; Aigner C; Bankfalvi A; Schmid KW; Mairinger FD
    Sci Rep; 2020 Oct; 10(1):18677. PubMed ID: 33122816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma.
    Salaroglio IC; Belisario DC; Bironzo P; Ananthanarayanan P; Ricci L; Digiovanni S; Fontana S; Napoli F; Sandri A; Facolmatà C; Libener R; Comunanza V; Grosso F; Gazzano E; Leo F; Taulli R; Bussolino F; Righi L; Papotti MG; Novello S; Scagliotti GV; Riganti C; Kopecka J
    J Exp Clin Cancer Res; 2022 Feb; 41(1):75. PubMed ID: 35197103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.